Render Target: SSR
Render Timestamp:
4/1/2025, 11:44:15 AM EDT
4/1/2025, 3:44:15 PM UTC
Commit: 461ca8d8fe5b1efd4c01fc87e5b5eb592e2d154a
XML generation date: 2025-03-25 22:05:23.957
Product last modified at: 2025-03-27T08:00:11.233Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TRIM8 (F3C3T) Rabbit mAb #85434

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 62
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TRIM8 (F3C3T) Rabbit mAb recognizes endogenous levels of total TRIM8 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro531 of human TRIM8 protein.

    Background

    Tripartite motif-containing protein 8 (TRIM8) is a RING E3 ubiquitin ligase and member of the TRIM family (1). It was originally termed glioblastoma-expressed RING-finger protein (GERP), encoded by a gene found on a chromosomal region characterized by frequent loss of heterozygosity in glioblastoma (2). The importance of TRIM8 in cancer and other pathological conditions has been described (reviewed in 3,4). Interestingly, TRIM8 has both suppressive and oncogenic activities in cancer. As a tumor suppressor, TRIM8 has the capacity to act in a positive feedback loop to enhance p53 function. TRIM8 is induced by p53 and leads to p53 stabilization by degrading MDM2 (5). In non-small cell lung cancer, TRIM8 functions as a tumor suppressor by targeting MYOF for degradation (6). Other studies illustrated that TRIM8 plays a role in promoting cell proliferation and invasion. TRIM8 regulates cytokine signaling through multiple mechanisms, including inhibition of SOCS1, a suppressor of cytokine signaling (7,8), potentiating TNF-α signaling, and promoting NF-κB activation by targeting TAK1 for K63-linked ubiquitination (9). TRIM8 also interacts with PIAS3, resulting in enhanced STAT3 signaling (10). In ovarian cancer, TRIM8 promotes proliferation by targeting VDAC2 for ubiquitination and degradation (11). In Ewing's sarcoma, TRIM8 promotes survival by targeting the driver fusion EWS/FLI for degradation (12).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.